Though stem cells and other regenerative medicine techniques hold enormous promise, they also face an equally large set of obstacles, ranging from research funding to reimbursement
Last summer, a collection of manufacturers and supporters formed an organization to address these issues, the Alliance for Regenerative Medicine, which is now beginning to take shape.
In September, the Alliance held its first official meeting and appointed executive officers. John Walker, CEO of stem cell company iPierian (San Francisco), will chair the organization. Charter members include Johnson & Johnson and Pfizer Inc. as well as research institutes, foundations, venture capital firms and makers of regenerative treatments.
The overall goal is to lobby for favorable policies in three areas: research, regulation and reimbursement. One aim is to ensure that researchers can gain access to funding, says Michael Werner, executive director at the Alliance and a partner at law firm Holland & Knight in Washington.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
How Industry Stakeholders View Medicare Advantage Expansion for Patients with Kidney Disease
July 7th 2025A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.